miR-329 inhibits papillary thyroid cancer progression via direct targeting WNT1

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Dysregulated microRNA-329 (miR-329) is implicated in tumor progression.
• The specific role of miR-329 in papillary thyroid cancer (PTC) is not well understood.

Purpose of the Study:

• To investigate the function and regulatory mechanisms of miR-329 in PTC.
• To explore the potential of miR-329 as a therapeutic agent for PTC.

Main Methods:

• Quantitative real-time PCR to assess miR-329 expression in PTC tissues and cell lines.
• In vitro assays (proliferation, colony formation) and in vivo tumor growth studies.
• Luciferase reporter assays to confirm direct binding of miR-329 to WNT1 3'UTR.
• Experiments using short interfering RNA (siRNA) for WNT1 and WNT1 overexpression vectors.

Main Results:

• miR-329 expression was significantly downregulated in PTC tissues and cell lines.
• miR-329 mimics suppressed PTC cell proliferation, colony formation, and tumor growth in vivo.
• miR-329 directly targets the 3'untranslated region of WNT1.
• WNT1 knockdown mimicked miR-329 overexpression effects, and WNT1 overexpression reversed miR-329's tumor-suppressive actions.

Conclusions:

• miR-329 acts as a tumor suppressor in PTC by inhibiting cell proliferation and growth.
• The miR-329/WNT1 axis is a key regulatory pathway in PTC progression.
• miR-329 holds promise as a potential therapeutic target for papillary thyroid cancer.